---
schema_version: "secwatch.filing_event.v1"
accession: "0000926617-23-000093"
form_type: "8-K"
ticker: "AWHL"
cik: "0000926617"
company_name: "Aspira Women's Health Inc."
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T05:58:38.308246+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aspira Women's Health Q3 product revenue up 9% to $2.2M; cash burn down 56% to $3.3M

## Summary
- Product revenue $2.2M (+9% YoY); OvaSuite volume 5,783 units (+5% YoY).
- OvaWatch tests reached 1,015 in Q3, now nearly 20% of total OvaSuite volume.
- Cash used in operations $3.3M, down 56% from $7.5M in Q3 2022; reiterated H2 2023 target $6-8M.
- Gross margin improved to 59.0% from 55.8% YoY; R&D and SG&A expenses each down >50% YoY.
- Raised $4.7M gross proceeds in registered direct offering; total cash $5.4M at Sep 30.

## SEC filing metadata
- accession: 0000926617-23-000093
- form_type: 8-K
- ticker: AWHL
- cik: 0000926617
- company_name: Aspira Women's Health Inc.
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/926617/000092661723000093/0000926617-23-000093-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/926617/000092661723000093/awh-20231113x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000926617-23-000093
- JSON: https://secwatch.observer/filing/0000926617-23-000093.json
- Plain text: https://secwatch.observer/filing/0000926617-23-000093.txt

## Key facts
- Earnings Releases
  Aspira Women's Health Inc. reported the three and nine months ended September 30, 2023 results: revenue $2,217,000.
  - Period: the three and nine months ended September 30, 2023
  - Revenue: $2,217,000
  - Result: reported results
  source text: leading sales at Sema4Genomics and Sonic Reference Laboratory, Inc.  Third Quarter 2023 Financial Highlights Product revenue for the three months ended September 30, 2023, was $2,217,000, an increase of 9%, compared to $2,037,000 for the same period in 2022. The increase in revenue was primarily due to an increase in OvaSuite test volume compared to the prior year,
  evidence_url: https://www.sec.gov/Archives/edgar/data/926617/000092661723000093/0000926617-23-000093-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.